Skip to main content
Clinical Trials/NCT02464267
NCT02464267
Completed
Not Applicable

Developing and Validating a Patient-reported Outcome Instrument to Monitor Symptom Management in Pulmonary Exacerbation of Patients Living With Cystic Fibrosis - Item Development

University of Zurich1 site in 1 country18 target enrollmentApril 2015
ConditionsCystic Fibrosis

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Cystic Fibrosis
Sponsor
University of Zurich
Enrollment
18
Locations
1
Primary Endpoint
Change in patient experience of symptom management
Status
Completed
Last Updated
8 years ago

Overview

Brief Summary

The aim of this study is to develop a reliable and valid instrument to measure symptom management (experience and / or management strategies) during exacerbation episodes in CF patients. For the development a sequential exploratory two phase mixed-method study will be applied. In a first step, up to 25 CF patients will be interviewed: approximately 15 CF patients who experienced at least one episode of exacerbation in the past year and approximately CF 10 patients who are currently experiencing an exacerbation. The latter group will be interviewed up to 3 times during and after the antibiotic treatment. The instruments initial item list will be developed on basis of the interviews. Up to five health professionals will rate the items' relevance. In a further step, items' clarity and relevance will be assessed by cognitive debriefing interviews with no more than 10 patients. In the last step (part III), the instrument's preliminary construct and concurrent validity and reliability will be tested in a larger sample up to 150 patients experiencing exacerbation. Patients will be asked to complete the newly developed questionnaires and a set of other questionnaires at one time point. For part III, ethic approval will be asked at a later date (2015).

Registry
clinicaltrials.gov
Start Date
April 2015
End Date
September 2017
Last Updated
8 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Part I A \& II:
  • Patients with a confirmed diagnosis of cystic fibrosis
  • Experience of at least one exacerbation during the last year requiring antibiotic treatment (oral or intravenous)
  • Patients with a confirmed diagnosis of cystic fibrosis
  • Experience of an acute exacerbation requiring antibiotic treatment (oral or intravenous)

Exclusion Criteria

  • Part I \& II
  • Do not speak or understand German
  • Inability to verbally communicate
  • Cognitive impairment

Outcomes

Primary Outcomes

Change in patient experience of symptom management

Time Frame: Patients will be followed up for 4 weeks after start of antibiotic treatment

Study Sites (1)

Loading locations...

Similar Trials